Andrew Donohue
Corporate Officer/Principal presso PolyActiva Pty Ltd.
Profilo
Andrew Donohue is currently the Head of Organic Chemistry at PolyActiva Pty Ltd.
He previously worked as a Senior Research Officer at The Walter & Eliza Hall Institute of Medical Research, a Senior Scientist at YM BioSciences Australia Pty Ltd., and a Principal at The Biomolecular Research Institute Ltd.
Donohue received his undergraduate and doctorate degrees from Monash University.
Posizioni attive di Andrew Donohue
Società | Posizione | Inizio |
---|---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Corporate Officer/Principal | 01/01/2010 |
Precedenti posizioni note di Andrew Donohue
Società | Posizione | Fine |
---|---|---|
The Walter & Eliza Hall Institute of Medical Research
The Walter & Eliza Hall Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Walter and Eliza Hall Institute of Medical Research provides medical research services. It undertakes research in a range of areas, preventing and treating diseases including breast, ovarian and blood cancers, type 1 diabetes, rheumatoid arthritis, coeliac disease and malaria. The firm’s research areas include bioinformatics, cancer biology, cell death, cell signaling, clinical translation, epigenetics, genomics, immunology, and inflammation and vaccine development. The company was founded in 1915 and is headquartered in Melbourne, Australia. | Corporate Officer/Principal | - |
YM BioSciences Australia Pty Ltd.
YM BioSciences Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., YM BioSciences Australia Pty Ltd. develops cancer treatment pharmaceuticals. The company is based in Melbourne, Australia. | Corporate Officer/Principal | - |
The Biomolecular Research Institute Ltd. | Corporate Officer/Principal | - |
Formazione di Andrew Donohue
Monash University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
The Walter & Eliza Hall Institute of Medical Research
The Walter & Eliza Hall Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Walter and Eliza Hall Institute of Medical Research provides medical research services. It undertakes research in a range of areas, preventing and treating diseases including breast, ovarian and blood cancers, type 1 diabetes, rheumatoid arthritis, coeliac disease and malaria. The firm’s research areas include bioinformatics, cancer biology, cell death, cell signaling, clinical translation, epigenetics, genomics, immunology, and inflammation and vaccine development. The company was founded in 1915 and is headquartered in Melbourne, Australia. | Commercial Services |
YM BioSciences Australia Pty Ltd.
YM BioSciences Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., YM BioSciences Australia Pty Ltd. develops cancer treatment pharmaceuticals. The company is based in Melbourne, Australia. | Health Technology |
The Biomolecular Research Institute Ltd. | |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
- Borsa valori
- Insiders
- Andrew Donohue